Show simple item record

dc.contributor.authorBadesha, Arshpreet Singh; email: arshpreet.badesha@student.manchester.ac.uk
dc.contributor.authorSingh Bains, Prab Rajan
dc.contributor.authorSingh Bains, Bal Rajan
dc.contributor.authorKhan, Taha
dc.date.accessioned2021-05-23T00:34:34Z
dc.date.available2021-05-23T00:34:34Z
dc.date.issued2021-05-06
dc.date.submitted2020-12-16
dc.identifierpubmed: 33965610
dc.identifierpii: S2213-333X(21)00210-9
dc.identifierdoi: 10.1016/j.jvsv.2021.04.014
dc.identifier.citationJournal of vascular surgery. Venous and lymphatic disorders
dc.identifier.urihttp://hdl.handle.net/10034/624672
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionHistory: received 2020-12-16, accepted 2021-04-18
dc.descriptionPublication status: aheadofprint
dc.description.abstractThis review aims to summarise the efficacy and safety of dedicated venous stenting for the treatment of obstructive chronic deep venous disease. The approaches to stenting and post-procedural management of different vascular units are also highlighted. MEDLINE and Embase were searched to identify relevant literature on dedicated venous stents published from January, 2010 to May, 2020. The patient population and study characteristics; procedural characteristics; and outcomes related to post-stenting symptoms, health-related quality of life, patency and complications were analysed. Sixteen single-arm observational studies were included from 2,366 studies identified from key-word searches. In total, 1,688 patients were included, of which 70.5% had post-thrombotic syndrome and the remainder had non-thrombotic iliac vein lesions. Nine studies (n = 848), stated whether lesions were stenotic (36.6%) or occlusive (63.4%). Seven studies did not report the lesion characteristics (n = 840). Eight different dedicated venous stent brands were employed. 73.4% of ulcers healed at last follow-up. The remaining symptomatic changes were described narratively; sustained improvements in pain, venous claudication and oedema following stenting were observed. Significant post-stenting improvements in health-related quality of life were noted, as measured by the Chronic Venous Insufficiency Questionnaire-20 instrument. Overall, the most frequently reported complications were in-stent occlusion (n = 204), in-stent stenosis (n = 149) and minor bleeding (n = 77). At 12 months, the primary patency ranged from 59% to 94%, whilst the secondary patency ranged 87% to 100%. The pooled-primary and secondary stent patency rates at 12 months were 74.0% and 90.4%, respectively. The incidence of major and minor bleeding was 1.9% and 4.7%, respectively; bleeding complications were more common in patients undergoing hybrid intervention. Deep venous stenting using dedicated venous stents is a safe technique to treat obstructive chronic deep venous disease and within the limitations of this study, is associated with good patency outcomes and symptomatic improvement. [Abstract copyright: Copyright © 2021. Published by Elsevier Inc.]
dc.languageeng
dc.sourceeissn: 2213-3348
dc.titleA systematic review and meta-analysis of the treatment of obstructive chronic deep venous disease using dedicated venous stents.
dc.typearticle
dc.date.updated2021-05-23T00:34:34Z
dc.date.accepted2021-04-18


This item appears in the following Collection(s)

Show simple item record